doi:https://doi.org/

Journal: Evidence-based Cardiology. 2018;11(4): 16‑18

Read: 2408 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

. Evidence-based Cardiology. 2018;11(4):16‑18. (In Russ.)

Использование инфографики авторами научных работ

References:

Lyman G.H., Culakova E., Poniewierski M.S., Kuderer N.M. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res 2018;164:Suppl 1:S112—S118.
Elting L.S., Escalante C.P., Cooksley C., et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164: 1653—1661.
Prandoni P., Lensing A.W., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484—348.
Ay C., Dunkler D., Marosi C., et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116:5377—5382.
Agnelli G., George D.J., Kakkar A.K., et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366:601—609.
Agnelli G., Gussoni G., Bianchini C., et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10: 943—949.
Raskob G.E., van Es N., Verhamme P., et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378:615—624.
Young A.M., Marshall A., Thirlwall J., et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018;36:2017—2023.
Khorana A.A., Francis C.W., Kuderer N.M., et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Thromb Res 2017;151:89—95.